Clinical Trial Update: Rapamycin in Relapsed Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of Rapamycin for relapsed acute lymphoblastic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED